ReviewCellular and molecular life sciences : CMLS2025
Circular RNAs and endothelial dysfunction: mechanistic crosstalk and emerging therapeutic perspectives.
Review in Cellular and molecular life sciences : CMLS, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
2 citing papers in PubMed.
- Chasing the FoxO in Metabolic Disorders: Novel Considerations for Oxidative Stress, Programmed Cell Death, Wnt, and the Gut Microbiome.Antioxidants (Basel, Switzerland) · 2026Review
- Agitation, Alzheimer's disease, and autophagy: mechanistic insights into aging pathways, gut microbiome, and artificial intelligence.Frontiers in immunology · 2026Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors.
Funding
Abstract
The dysfunction of endothelial cells (ECs) plays an essential role in the pathogenesis and development of a wide range of complex human diseases. These cells are important for regulating the functions of capillaries. Alterations in the vascular endothelium are associated with a broad spectrum of diseases, including atherosclerosis, stroke, hypertension, diabetes, coronary artery disease (CAD), venous thrombosis, cancer, and related angiogenesis disorders. Consequently, impaired endothelial function is recognized as a characteristic feature of numerous human diseases. circular RNAs (circRNAs) have recently expanded recognition as critical contributors to cellular processes, and their potential implications in endothelial dysfunction-related diseases have gained interest. While studies have extensively explored the roles of non-coding RNAs in endothelial dysfunction-related disease, the understanding of circRNAs in this context remains unclear. In this review, we aim to shed light on the mechanisms of circRNAs and their effect on endothelial dysfunction-related diseases. The investigation of circRNAs in endothelial dysfunction-related diseases such as atherosclerosis, hypertension, diabetes, and CAD holds great promises for uncovering innovative insights into disease pathogenesis and developing novel therapeutic approaches.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.